SGMO -20% on interim phase-1/2 data for SB-913: https://www.prnewswire.com/news-releases/sangamo-announces-16-week-clinical-results-including-reductions-in-glycosaminoglycans-in-phase-12-trial-evaluating-sb-913-a-zinc-finger-nuclease-genome-editing-treatment-for-mps-ii-hunter-syndrome-300706835.html